期刊文献+

美托洛尔治疗慢性心力衰竭的Meta分析 被引量:5

A Meta-analysis on treatment of chronic heart failure with Metoprolol in China
下载PDF
导出
摘要 目的评价美托洛尔治疗慢性心力衰竭的有效性。方法计算机检索2000年至2015年1月Pubmed、Embase、万方数据库、中国学术期刊全文数据库(CNKI)、维普数据库(VIP),收集美托洛尔治疗慢性心力衰竭的随机对照试验(RCTs),按纳入和排除标准由2名评价者独立选择试验、提取资料,交叉核对并进行方法学质量评估。使用RevMan5.3软件进行Meta分析。结果共纳入7项研究,582例患者。结果显示,常规治疗基础上联用美托洛尔治疗慢性心力衰竭显著优于常规治疗对照组(RR=4.83,95%CI2.72~8.58.P〈0.01);联用美托洛尔可增加射血分数(LVEF)(WMD=7.11,95%CI6.44~7.77,P〈0.01);降低左室舒张末期内径(LVEDD)(WMD=-4.89,95%CI-5.58~-4.19,P〈0.01);降低左室收缩末期内径(LVESD)(WMD=-3.68,95%CI-4.59~-2.78,P〈0.01);降低BNP(WMD=-211.58,95%CI-222.71~-200.45,P〈0.01)。结论现有证据显示,联合美托洛尔治疗可改善慢性心力衰竭临床疗效及心功能指标。因纳入研究较少,样本量小,且质量不高,故仍需开展大样本、多中心、高质量的随机对照试验加以验证。 Objective To review the effectiveness of Metoprolol in the treatment of chronic heart failure (CHF). Methods The databases of PubMed, Embase, Infrastructure (CNKI) and VIP Database were retrieved WanFang Database, China National Network Knowledge with computer for collecting randomized controlled trials (RCTs) about the treatment of CHF with Metoprolol from 2000 to January 2015. All data was selected, extracted, cross-checked and given methodological quality evaluation by two independent reviewers according to inclusion and exclusion criterions, and then a Meta-analysis was conducted by using RevMan 5.3. Results There were totally 7 RCTs included involving 582 patients. The results showed that the curative effect on CHF was significantly better in group combining routine therapy and Metoprolol (combining group) than that in control group (RR=4.83, 95%17,1 2.72-8.58, P〈0.01 ). In combining group, LVEF increased (WMD=7.11, 95%CI 6.44-7.77, P〈0.01). LVEDD decreased ( WMD=-4.89, 95%CI -5.58--4.19, P〈0.01 ). LVESD decreased (WMD=-3.68, 95%CI -4.59--2.78, P〈0.01 ). BNP decreased ( WMD=-211.58, 95%CI -222.71 --200.45, P〈0.01 ). Conclusion The existing evi- dences indicate that Metoprolol can improve the curative effect and cardiac functional indexes. Due to the limitation of the included studies, more large-sample, multiple-center and high-quality RCTs are required.
出处 《中国心血管病研究》 CAS 2015年第7期617-620,共4页 Chinese Journal of Cardiovascular Research
基金 湖北省基金重点项目(项目编号:2014CFA061)
关键词 美托洛尔 慢性心力衰竭 META分析 Metoprolol Chronic heart failure Meta-analysis
  • 引文网络
  • 相关文献

参考文献12

二级参考文献80

  • 1孙宝贵,汪玮.慢性心力衰竭治疗中血管紧张素转换酶抑制剂的应用[J].中国实用内科杂志,2005,25(7):582-584. 被引量:55
  • 2吴学思.β受体阻滞剂在心力衰竭治疗中的地位及应用要点[J].心血管病学进展,2006,27(2):126-129. 被引量:16
  • 3王林,马金萍,党群,陈康寅,李永健,李喜元,陈树涛,丛洪良,李广平,黄体钢.老年慢性心力衰竭住院患者2656例的回顾性分析[J].中华老年医学杂志,2006,25(8):565-569. 被引量:40
  • 4[1]Massie BM,Shan NB.Evolving trends in the epidem iologic failure:Rationale for preventive strategies and comprehensive disease management.Am Hear J,1997,133:703-712.
  • 5[2]CIBIS-Ⅱ Investigators and Committees the Cardiac Insuffic iency Bisoprolol StudyⅡ (CIBIS-Ⅱ):a random ized trial.Lancet,1999,353:9-13.
  • 6[3]Wikstrand J,Hjalmarson A,Waagstein F,et al.Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure:analysis of the experience in metprolol CR/XL randomized intervention trial in CHF (MERIT-HF).J Am Coll Cardiol,2002,40:491-498.
  • 7[4]Packer M,coats AJS,Fowler MC,et al.Effect of carvedilol on survival in severe chronic heart failure.N EngI J Med,2001,344:1651-1658.
  • 8[5]Packer M,Cohn JN,Abraham WT,et al.Consensus recommerdations for the management of chronic heart failure.Am J cardiol,1999,83:1-38.
  • 9[6]Satw ani S,Dec GW.β-adrenergic blockers in heart failure:review of mechanisms of action and clinical outcomes.J Curnal of Card Iovascular Pham Acology and Therapeclics,2004,9:243-255.
  • 10[7]Packer H.Betaradrenergic blockade in chronic heart failure:principles,progress,and practice.Prog Cardiovasc Dis,1999,41(Suppl):S39-552.

共引文献2834

同被引文献59

二级引证文献60

;
使用帮助 返回顶部